Fresh Partnerships and Scholarship Grants for Better Healthcare Delivery - Research Report on Express Scripts, Aetna, UnitedHealth Group, IDEXX, and Abaxis
NEW YORK, August 1, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Express Scripts Holding Company (NASDAQ: ESRX), Aetna Inc. (NYSE: AET), UnitedHealth Group Incorporated (NYSE: UNH), IDEXX Laboratories, Inc. (NASDAQ: IDXX), and Abaxis, Inc. (NASDAQ: ABAX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Express Scripts Holding Company Research Report
On July 29, 2013, Express Scripts Holding Company (Express Scripts) reported financial results for Q2 2013. The Company announced that income from continuing operations attributable to Express Scripts shareholders was $558.3 million, or $0.67 per diluted share, in Q2 2013, compared to $150.0 million, or $0.18 per diluted share, in Q2 2012. Revenues totaled at $26.4 billion in Q2 2013, representing 3.9% YoY decline. "As we head toward 2014 and the introduction of insurance changes, additional costly regulations, escalation of brand drug prices, and increased specialty drug utilization, our clients face unprecedented challenges to manage the cost and complexity of the pharmacy benefit," said George Paz, Chairman and CEO of Express Scripts. "Our clinical specialization, advanced application of the behavioral sciences, and ability to leverage actionable data allow us to drive down costs, reduce waste, and improve health in ways no other company can." For Q3 2013, the Company expects adjusted diluted EPS from continuing operations attributable to Express Scripts to range between $1.05 and $1.09. The Full Research Report on Express Scripts Holding Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/91a7_ESRX]
Aetna Inc. Research Report
On July 24, 2013, Aetna Inc. (Aetna) announced that it has joined National Association of Counties (NACo) as a new Premier Member and a Healthy Counties Initiative Sponsor. "We are pleased to work alongside of NACo on its mission, and to engage with community leaders on overcoming barriers to ensure the health and wellness of individuals," said Cain Hayes, President of Public Sector and Labor businesses at Aetna. Aetna reported that as a Premier Member of NACo it will support the governmental organization to promote community public health prevention and wellness programs, including increased physical activity and healthy eating. In 2011, NACo launched the Healthy Counties Initiative to enhance public-private partnerships in local health care delivery, improve individual and community health, and assist counties to effectively implement federal health care reform. The Full Research Report on Aetna Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/cbe9_AET]
UnitedHealth Group Incorporated Research Report
On July 24, 2013, UnitedHealth Group Incorporated (UnitedHealth Group) announced that United Health Foundation, a not-for-profit, private foundation established by the UnitedHealth Group, will award scholarship to nearly $2 million to 175 students from diverse, multicultural backgrounds, as a part of the Foundation's Diverse Scholar Initiative, which aims at increasing diversity in the health care workforce by supporting promising future health professionals. "We know patients do best when they are treated by people who understand their language and culture," said Kate Rubin, President of United Health Foundation. By the end of 2013, United Health Foundation expects to increase this support to more than $10 million. The Full Research Report on UnitedHealth Group Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/73e5_UNH]
IDEXX Laboratories, Inc. Research Report
On July 23, 2013, IDEXX Laboratories, Inc. (IDEXX) reported Q2 2013 financial results. The Company's revenues in Q2 2013 increased 5.0% YoY to $352.6 million, whereas organic revenue grew 5.5% YoY. Diluted EPS during Q2 2013 grew 8.8% YoY to $0.99. "I am pleased with the Companion Animal Group acceleration in sequential quarter organic revenue growth from 3.6% in the first quarter to 6.7% in the second quarter, reflecting strong growth in instrument consumables and reference lab services," said Jonathan Ayers, Chairman and CEO of IDEXX. "Our confidence in a projected 10% organic revenue growth in the second half of the year comes from a favorable compare to the second half of 2012, the impact of increased sales capacity for digital and customer information management system sales, the growing adoption of VetConnect PLUS with its unique patient-centric approach to diagnostic information, and our transformation of the North American diagnostic sales organization." The Full Research Report on IDEXX Laboratories, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/bf62_IDXX]
Abaxis, Inc. Research Report
On July 25, 2013, Abaxis, Inc. (Abaxis) reported financial results for Q1 FY 2014 (period ended June 30, 2013). The Company generated revenues of $43.2 million, up 2.7% YoY. Diluted EPS during the quarter was up 7.7% YoY to $0.14. "The results for the quarter continue to reflect the impact of our transition from a direct sales model to strategically partnering with industry leading distributors to sell our products into the expanded markets that these partners have developed," said Clint Severson, Chairman and CEO of Abaxis. Severson added, "Overall, we are pleased with the progress being achieved and expect improved operational and financial results as we move through fiscal 2014 and beyond." The Full Research Report on Abaxis, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/ec55_ABAX]
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
SOURCE Analysts' Corner
More by this Source
Strategic Collaborations, Clinical Studies, Regulatory Update, and Other Corporate Announcements - Research Report on OncoMed, Auxilium Pharma, BioTelemetry, Progenics Pharma, and Ambit Biosciences
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.